C12N 2760/14122
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/14122 (New viral proteins or individual genes, new structural or functional aspects of) appears on 75 US grants and 139 published applications in this corpus.
Search patents in C12N- Granted patents
- 75
- Published applications
- 139
- Assignees
- 89
- Inventors
- 198
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 2 | 5 |
| 2004 | 1 | 5 |
| 2005 | 2 | 6 |
| 2006 | 1 | 5 |
| 2007 | 2 | 4 |
| 2008 | 0 | 1 |
| 2009 | 3 | 2 |
| 2010 | 4 | 7 |
| 2011 | 2 | 3 |
| 2012 | 3 | 3 |
| 2013 | 2 | 2 |
| 2014 | 2 | 2 |
| 2015 | 2 | 5 |
| 2016 | 1 | 9 |
| 2017 | 4 | 11 |
| 2018 | 4 | 6 |
| 2019 | 5 | 6 |
| 2020 | 6 | 10 |
| 2021 | 8 | 8 |
| 2022 | 7 | 7 |
| 2023 | 4 | 7 |
| 2024 | 3 | 14 |
| 2025 | 6 | 5 |
| 2026 | 1 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Antiviral structurally-stabilized Ebolavirus peptides and uses thereof6 Oct 2026US 12,753,208 B2Dana-Farber Cancer Institute, Inc.
- VLP-based monovalent ebola vaccines and methods of making and using same30 Sep 2025US 12,427,190 B2Children's Hospital Medical Center
- Adeno-associated virus (AAV) producer cell lines9 Sep 2025US 12,410,436 B2Lonza Houston, Inc.
- Dendritic cell-targeting universal vaccine for influenza infection29 Jul 2025US 12,370,254 B2University of Manitoba
- Recombinant biologically contained filovirus vaccine1 Jul 2025US 12,343,390 B2Wisconsin Alumni Research Foundation (WARF)
- Purification of viruses and viral like particles8 Oct 2026US 2026/0308616 A1Interius Biotherapeutics, Inc.
- Vaccines and methods6 Aug 2026US 2026/0224686 A1Cambridge Enterprise Limited
- Immunogenic ebolavirus fusion proteins and related methods23 Jul 2026US 2026/0207728 A1CZ Biohub SF, LLC
- Sarna delivery system, preparation method therefor and use thereof23 Apr 2026US 2026/0110000 A1Zhejiang Free Trade Zone Hongan Base Biotechnology Co., Ltd.
- Adeno-associated virus (aav) producer cell lines2 Apr 2026US 2026/0092284 A1Lonza Houston, Inc.
Most cited
By later US patents
- Adenovirus vector with multiple expression cassettes110US 6,544,780 B1GenPhar, Inc. · 2003
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations38US 8,394,386 B2The Trustees of the University of Pennsylvania · 2013
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions37US 10,568,972 B2CureVac AG · 2020
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions37US 11,135,312 B2CureVac AG · 2021